Xingting Guo

Xingting Guo

Auto-generated profile, based on publicly available information

Xingting Guo

Precogify Pharmaceutical Co. Ltd, Beijing, China

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 November 2026 in Cells
Verified
Journal Article
Open access
PDF file
JKJiJingweingwei Kang
JiJingweingwei Kang
SDShigang Ding
Shigang Ding
XGXingting Guo
Xingting Guo
Gastric precancer is conventionally staged as a linear histological sequence, but it develops within a patchy, continuously remodeling mucosa. This narrative review reframes gastric carcinogenesis as a multiscale spatial process in which epithelial states, clonal gland dynamics, immune–stromal neighborhoods, regional Helicobacter pylori (H. pylori) and non-H. pylori colonization, and metabolic or physicochemical gradients may jointly shape local risk. Gland-resolved studies show that metaplasia may expand through fission and remain clonally continuous with dysplasia in selected lesions, whereas broad genomic and epigenetic field alterations may also support independent tumor emergence. Single-cell and spatial analyses identify hybrid, stem-like, and proliferative epithelial states embedded within evolving multicellular niches, although most evidence remains cross-sectional and biased toward established cancer. We therefore propose a non-deterministic model in which injury drives gland loss and niche remodeling; metaplastic clones expand and diversify; local ecological pressures may select high-risk states; and only a minority of glands cross the neoplastic threshold. This remains a working hypothesis, particularly for niche-driven selection of human precancerous clones. Clinically, the framework is consistent with the prognostic value of metaplastic extent, corpus involvement, and the Operative Link on Gastritis Assessment (OLGA) and Operative Link on Gastric Intestinal Metaplasia Assessment (OLGIM) systems, while defining the longitudinal, topographically annotated, gland-resolved studies needed to determine whether spatial risk maps add clinical value beyond established staging.

30 May 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
FCFeng Chen
Feng Chen
XLxiaoying lou
xiaoying lou
XGXingting Guo
Xingting Guo
YGYe Guo
Ye Guo
YHYuan Huang
Yuan Huang
WCWei Cui
Wei Cui
Genomic mutations in pancreatic ductal adenocarcinoma (PDAC) are hypothesized to drive poor prognosis and low response rates to targeted therapy through crosstalk among downstream regulatory networks. Here, we apply a causal inference-based approach, Mutation-Upstream-of-Metabolomic-Signature (MUMS), to show that prognostic serum metabolomic signatures can capture such crosstalk and reflect the collective impact of mutation-driven networks on tumor progression. We identify a panel of nine serum metabolites that predicts survival outcomes across multiple independent PDAC cohorts. MUMS analysis further identifies and functionally validates GRPEL1 as a tumor-promoting gene whose downstream metabolic signature converges with that of the mTOR/PI3K/Akt signaling pathway. Consistently, GRPEL1 sensitizes PDAC cells to proliferation arrest induced by mTOR inhibition. Together, our findings provide proof-of-concept evidence that serum metabolic signatures can reflect crosstalk within the tumor mutational landscape. These co-regulatory patterns offer a framework for uncovering new therapeutic targets and guiding the design of rational combination therapies.

16 November 2026 in Biology
Verified
Journal Article
Open access
PDF file
KZKangle Zhai
Kangle Zhai
GZGuangmin Zuo
Guangmin Zuo
YWYue Wen
Yue Wen
YLYaxin Lou
Yaxin Lou
XLXin Liu
Xin Liu
XGXingting Guo
Xingting Guo
Detection and endoscopic removal of EGC effectively reduced GC-caused mortality, yet no effective non-invasive screening approaches have been clinically used. Gastric juice integrates tissue- and gastric-microbiome-derived metabolites, making it a promising biofluid for screening EGC. To systematically profile metabolic reprogramming in gastric juice during gastric tumorigenesis, we carried out untargeted metabolic profiling in the discovery cohort enrolling patients at different stages along Correa’s cascade. We identified similar metabolic landscapes between HGD and EGC patients, which significantly differed from those of gastritis and intestinal metaplasia stages. These altered metabolites were subjected to origin analysis, revealing an association of both tumorigenesis-induced tissue metabolic reprogramming and gastric microbiome metabolic reprogramming, as supported by catalytic enzyme changes between tumor and adjacent normal tissues, and by bacteria-derived indole metabolites that correlated with altered gastric bacteria in GC patients. Least absolute shrinkage and selection operator (LASSO) was used for biomarker screening, and the selected metabolites were transferred into MRM-based targeted metabolic detection. A 4-metabolite panel-based diagnostic model was established in the discovery cohort and evaluated in an independent validation cohort, yielding an AUC of 0.90 (90.0% sensitivity, 79.0% specificity), with all three HGD and 20 of 23 EGC cases correctly classified. With the aid of endogastric capsules for non-invasive acquisition of gastric juice, our gastric juice metabolite-based test provides proof-of-concept evidence for its clinical utility in the early detection of GC and precancerous dysplasia.